Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

St. Thomas' Hospital
London
SE1 7EH


PARACHUTE III Pressure Volume Loop Sub-Study

Stopped

Open to: All Genders

Age: 18 Years - 79 Years

Medical Conditions

Heart Failure
Myocardial Infarction


Study summary

The primary objective is to assess the longterm safety of the CardioKinetix Parachute Implant and Delivery System in the partitioning of the left ventricle in patients with heart failure due to ischemic heart disease. This sub-study has the additional assessment of improvement in Pressure Volume Loop and corresponding MSCT to allow improved monitoring of heart improvement after therapy. The PV Loop Substudy studies he effects of the Parachute Implant on pressure and volume as functional parameters of the Left Ventricle.

While current therapies for heart failure (including but not limited to: medical management, cardiac resynchronization and ICDs) may represent the best treatment available today for the majority of HF patients, the medical community recognizes that pharmacologic therapy has been optimized to nearly the extent that is possible, and that any incremental improvements in the management of HF patients will now come from device based therapies. With this background, CardioKinetix has developed a catheter-based intravascular approach to ventricular partitioning using an implantable device. The purpose of this study is to assess the longterm safety of using the CardioKinetix Parachute device to isolate the malfunctioning portion of the left ventricle in patients with symptoms of HF due to ischemic heart disease.


Key dates

The recruitment start and end dates are as follows:

Nov 2013

Jan 2016

Study type

Observational

Who can take part?

You can take part if:


Inclusion Criteria:

- Candidates for this study must meet ALL of the following inclusion criteria:

1. Akinesis or dyskinesis due to myocardial infarction limited to anteroapical region

2. Subject is not hospitalized at time of enrollment.

3. NYHA Class at time of enrollment, either:

- NYHA Class III or Ambulatory IV - if predominant during the 3-month period prior to enrollment

- NYHA Class II - if diagnosed with NYHA Class III or IV during 3-month period prior to enrollment

4. LVEF >15 or% and ≤ 40% as measured by echocardiography.

5. Post LV MI structural heart dysfunction represented by LV wall motion abnormality (WMA) by echocardiography.

6. Eligible for cardiac surgery

7. Between 18 and 79 years of age (inclusive)

8. Receiving appropriate medical treatment for heart failure according to the ACC/AHA 2009 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult during the three months prior to enrollment

9. Provide written informed consent

10. Agree to the protocol-required follow-up

Exclusion Criteria:

Candidates will be excluded from the study if ANY of the following conditions apply:

1. Untreated clinically significant coronary artery disease requiring intervention.

2. Acute MI (see MI definition) within 60 days of enrollment or patients with suspected evolving MI at time of enrollment

3. Cardiogenic shock within 72 hours of enrollment

4. Revascularization procedure (PCI or CABG) within 60 days of enrollment

5. Patient has received a pacemaker, ICD, or CRT device within 60 days of enrollment

6. History of aborted sudden cardiac death, if patient has not received an ICD and has potentially lethal ventricular arrhythmia, VT or VF

7. A known hypersensitivity or contraindication to aspirin, heparin, warfarin, nitinol (titanium and nickel alloy), or sensitivity to contrast media, which cannot be adequately pre medicated.

8. Aortic valve replacement or repair

9. Blood dyscrasia, history of bleeding diathesis or coagulopathy, or hypercoagulable states.

10. Active peptic ulcer or GI bleeding within the past 3 months

11. Patient has suffered a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months

12. History of Kawasaki's disease

13. Patient on dialysis or expected to require hemodialysis within 12 months

14. Patient has chronic liver disease

15. Impaired renal function that places patient at risk of contrast induced renal failure

16. Ongoing sepsis, including active endocarditis.

17. Co-morbidities associated with a life expectancy of less than 12-months or there are factors making echo and clinical follow-up difficult (no permanent address, etc.)




You may not be able to take part if:

This is in the inclusion criteria above


Where can I take part?

Below are the locations for where you can take part in the trial.

  • St. Thomas' Hospital
    London
    SE1 7EH

Funders/Sponsors


The study is sponsored by CardioKinetix, Inc .



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.

Is this study information helpful?

What will you do next?


Read full details

for Trial ID: NCT02241837

Last updated

This page is to help you find out about a research study and if you may be able to take part

The information is provided by researchers and we rely on them to keep it up-to-date. You can see more information by clicking on the 'Read full details' link above.

To take part, please print or share the study information with your GP/healthcare provider or contact the research team directly.